Aquila Diagnostic Systems Inc. is a privately held Canadian company commercializing its innovative Accutas solution for a point-of-care molecular (DNA/RNA) diagnostic testing system. The patented Accutas solution provides low cost, laboratory quality diagnostics at the point-of-care, eliminating cost and inconvenience of waiting days or weeks for laboratory results to be returned and the subsequent follow-up visit or treatment. Aquila is preparing to enter large markets for the companion animal and food production sectors.

Latest News

posted on February 27, 2017 Aquila Diagnostic Systems Inc. to Present at Venture Summit West
Aquila Diagnostics is pleased to announce that has it been selected to present at the third annual Venture Summit West in Mountain View California on February 28-March 1.


posted on June 24, 2016 Aquila featured in Alberta Venture magazine
24 June 2016 – Biotech startup firm finds a (small) pot of gold
Aquila Diagnostics has been toughing it out in the biotech-startup sphere for more than six years. Finally, a little light in the tunnel.


posted on June 16, 2016 Aquila Diagnostic Systems Inc. Raises $1.75 Million Investment in Series A Financing June 16, 2016 - Aquila Diagnostic Systems Inc., announces the closing of a $1.75 million Series A financing round with Benslie International Ltd. 



“This new technology... opens up the possibility of using a simple and highly sensitive molecular test at the point-of-care for the diagnosis of malaria and other blood-borne infections.”
Chief Scientific Officer Mark Perkins, Foundation for Innovative New Diagnostics (FIND), Geneva, in a favourable assessment showing Aquila’s Accutas™ diagnostic system achieved results superior to current malaria testing systems.


National Research Council
Alberta Innovates
Broadport Canada Inc
nanobridge small
Western Economic Diversification Canada 120w
Sustainable Poultry

4-034 National Institute for Nanotechnology, 11421 Saskatchewan Drive, Edmonton, Alberta, Canada   T6G 2M9

   Subscribe to our newsletter